GAITHERSBURG, Md., Nov. 10,
2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its Matrix-M™
adjuvant, today announced that it will participate in the Jefferies
London Healthcare Conference.
|
Conference
Details:
|
|
|
|
Fireside
Chat
|
|
|
Date:
|
Wednesday, November 15,
2023
|
|
Time:
|
9:00 – 9:25 a.m.
Greenwich Mean Time (GMT)
|
|
Location:
|
London
|
|
Moderator:
|
Roger Song, M.D., CFA,
Equity Analyst
|
|
Novavax
participants:
|
John C. Jacobs,
President and Chief Executive Officer and
Filip Dubovsky, M.D.,
President, Research & Development
|
|
|
|
|
Conference
|
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Wednesday, November 15,
2023
|
Recordings
A replay of the recorded fireside session
will be available through the Events & presentations page of
the Company's website at ir.novavax.com for 45 days from the
date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to protect against serious infectious diseases.
Novavax, a global company based in Gaithersburg, Md., U.S.,
offers a differentiated vaccine platform that combines a
recombinant protein approach, innovative nanoparticle technology
and Novavax's patented Matrix-M adjuvant to enhance the immune
response. Focused on the world's most urgent health challenges,
Novavax is currently evaluating vaccines for COVID-19, influenza
and COVID-19 and influenza combined. Please
visit novavax.com and LinkedIn for more
information.
Please visit novavax.com and LinkedIn for more
information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-jefferies-london-healthcare-conference-301984205.html
SOURCE NOVAVAX, INC